Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 1, 2007, Pages 102-108

  Radtke, K P ^a,c   Griffin, J H ^b   Riceberg, J ^b   Gale, Andrew J ^b  

^a BAYER CORPORATION   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c Biolex Therapeutics   (United States)

Author keywords

Disulfide bond; Factor VIII; Hemophilia A; Rotational thromboelastogram

Indexed keywords

BLOOD CLOTTING FACTOR 8A; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN;

ARTICLE; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BLOOD SAMPLING; CONTROLLED STUDY; DISULFIDE BOND; DRUG HALF LIFE; HEMOPHILIA A; HUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; THROMBOELASTOGRAPHY; WILD TYPE;

BLOOD COAGULATION; CELL LINE; COAGULANTS; DISULFIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; FACTOR VIII; FACTOR VIIIA; HALF-LIFE; HEMOPHILIA A; HUMANS; MUTATION; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; THROMBIN; THROMBIN TIME; TRANSFECTION; WHOLE BLOOD COAGULATION TIME;

EID: 33845549376     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02283.x     Document Type: Article

References (22)

1. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-96.
2. Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - a meta-analysis. Haemophilia 2003; 9: 251-60.
3. Pipe SW. The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost 2005; 3: 1692-701.
4. Saenko EL, Ananyeva NM, Shima M, Hauser CA, Pipe SW. The future of recombinant coagulation factors. J Thromb Haemost 2003; 1: 922-30.
5. Gale AJ, Radtke KP, Cunningham MA, Chamberlain D, Pellequer JL, Griffin JH. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost 2006; 4: 1315-22.
6. Gale AJ, Pellequer JL. An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa. J Thromb Haemost 2003; 1: 1966-71.
7. Lollar P, Parker ET. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem 1991; 266: 12481-6.
8. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27: 81-90.
9. Mesters RM, Houghten RA, Griffin JH. Identification of a sequence of human activated protein C (residues 390-404) essential for its anticoagulant activity. J Biol Chem 1991; 266: 24514-9.
10. Dargaud Y, Luddington R, Baglin TP. Elimination of contact factor activation improves measurement of platelet-dependent thrombin generation by calibrated automated thrombography at low-concentration tissue factor. J Thromb Haemost 2006; 4: 1160-1.
11. Hemker HC, Giesen P, Al Dierri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
12. Hemker HC, Beguin S. Thrombin generation in plasma: Its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-8.
13. Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17.
14. Pipe SW, Eickhorst AN, McKinley SH, Saenko EL, Kaufman RJ. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: Evidence for nonproteolytic inactivation of factor VIIIa in vivo. Blood 1999; 93: 176-83.
15. Lollar P, Parker ET, Fay PJ. Coagulant properties of hybrid human/ porcine factor VIII molecules. J Biol Chem 1992; 267: 23652-7.
16. Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 3: 2039-43.
17. O'Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: Role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997; 77: 825-8.
18. O'Donnell J, Mumford AD, Manning RA, Laffan M. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000; 83: 10-13.
19. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
20. Taylor FB, Hoogendoorn H, Chang ACK, Peer G, Nesheim ME, Catlett R, Stump DC, Giles AR. Anticoagulant and fibrinolytic activities are promoted, not retarded, in vivo after thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein C. Blood 1992; 79: 1720-8.
21. Rick ME, Popovsky MA, Krizek DM. Degradation of factor VIII coagulant antigen by proteolytic enzymes. Br J Haematol 1985; 61: 477-86.
22. Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.